An observational study in Alzheimer Disease, Dementia and Neurodegenerative Diseases, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2024-03-06.
Sponsored by Central Hospital, Nancy, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alzheimer Disease by Central Hospital, Nancy, France — 9 open to participants now, 9 under way, none of them phase 3. Alzheimer Disease · Central Hospital, Nancy, France.
Among the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France, this one is the only one that started in 2013, is one of 8 observational ones, and was the 5th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →9 of the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18–99
Central Hospital, Nancy, France · Sites in France
Ages 18–80
Central Hospital, Nancy, France · Sites in France
Central Hospital, Nancy, France · Sites in France
Ages 25–65 · Healthy volunteers
Central Hospital, Nancy, France · Sites in France
Ages 60+
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2013.
This study's planned enrollment of 50,000 is above the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 77 across the 9 interventional studies, 65 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
2 of the studies in Alzheimer Disease by Central Hospital, Nancy, France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07947446Central Hospital, Nancy, FranceCHUCOLATE: Current Knowledge and Prevalence of LATE-NC in Geriatric Memory Clinics at a Memory Center in Lorraine | 2026-12-31 |
| NCT06825663Central Hospital, Nancy, FranceMarker of Brain Insulin Resistance in AD Prognosis | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Alzheimer Disease by Central Hospital, Nancy, France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.
All consenting patients submitted to a lumbar punction in the context of dementia diagnosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CSF collection constitution to have samples available for assessing new Alzheimer's biomarker
Each CSF collected in the context of dementia diagnosis were conserved to be used in other studies on Alzheimer's or dementia biomarkers. Futre studies that will use collected CSF to assess new biomarkers will be conduced under a new protocol describing scientific contexte, specific aims and time frame necessary to achieve them.
Time frame: 50 years
Started Jul 2013 (actual). Primary completion is estimated for Dec 2050, 449 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 449 months is above that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →